Aernoud Fiolet

228 Chapter 8 REFERENCES 1. Vergallo R, Crea F. Atherosclerotic Plaque Healing. N. Engl. J. Med. 2020;383:846–857. 2. Libby P. Inflammation in Atherosclerosis-No Longer a Theory. Clin. Chem. 2021;67:131–142. 3. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 2017;377:1119–1131. 4. EMA. Canakinumab Novartis: Withdrawal of the marketing authorisation application. Available at: https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/surfaxin#key- facts-section. Accessed March 24, 2021. 5. Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH. Update on colchicine, 2017. Rheumatology (Oxford). 2018;57:i4–i11. 6. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237–241. 7. Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Semin. Arthritis Rheum. 2015;45:341–350. 8. Fiolet ATL, Nidorf SM, Mosterd A, Cornel JH. Colchicine in Stable CoronaryArtery Disease. Clin. Ther. 2019;41:30–40. 9. Tardif J-CC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 2019;381:2497–2505. 10. Bouabdallaoui N, Tardif JC, Waters DD, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur. Heart J. 2020;41:4092–4099. 11. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N. Engl. J. Med. 2020;383:1838–1847. 12. Nidorf SM, Fiolet ATL, Eikelboom JW, et al. The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. Am. Heart J. 2019;218:46–56. 13. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N. Engl. J. Med. 2009;361:1045–1057. 14. Gencer B, Mach F, Murphy SA, et al. Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction A Prespecified Secondary Analysis From the FOURIER Trial. 2020;02115:1–6. 15. Collet J-P, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2020;00:1–79. 16. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2018;39:119–177. 17. Everett BM. Residual Inflammatory Risk: A Common and Important Risk Factor for Recurrent Cardiovascular Events. J. Am. Coll. Cardiol. 2019;73:2410–2412. 18. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease analysis from Fourier. Circulation 2018;138:756–766. 19. Bonaca MP, Storey RF, Theroux P, et al. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. J. Am. Coll. Cardiol. 2017;70:1368–1375. 20. Bainey KR, Welsh RC, Connolly SJ, et al. Rivaroxaban plus aspirin versus aspirin alone in patients with prior percutaneous coronary intervention (COMPASS-PCI). Circulation 2020:1141–1151.